Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CTX-10726 |
| Synonyms | |
| Therapy Description |
CTX-10726 is a tetravalent bispecific antibody targeting PDCD1 (PD-1) and VEGFA, which potentially inhibits tumor angiogenesis and induces antitumor immune activity (J Immunother Cancer 2025;13(suppl_2):Abstract 1151). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CTX-10726 | CTX10726|CTX 10726 | PD-L1/PD-1 antibody 137 VEGFA Antibody 6 | CTX-10726 is a tetravalent bispecific antibody targeting PDCD1 (PD-1) and VEGFA, which potentially inhibits tumor angiogenesis and induces antitumor immune activity (J Immunother Cancer 2025;13(suppl_2):Abstract 1151). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07419841 | Phase I | CTX-10726 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Not yet recruiting | USA | 0 |